Potential STAT3 inhibitors can decrease the production of ROS and down-regulate phosphorylation of STAT3 and Bcl-2, restoring sensitivity to radiation, which offers an effective approach for treating triple-negative breast cancer cells [68]. The gene discussed is BCL2; the disease is triple-negative breast carcinoma.